![]() | |
Clinical data | |
---|---|
Other names | Chloro-IB-MECA; 2-Cl-IB-MECA |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.162.091 |
Chemical and physical data | |
Formula | C18H18ClIN6O4 |
Molar mass | 544.73 g·mol−1 |
3D model (JSmol) | |
| |
|
Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is developed by Can-Fite for non-alcoholic fatty liver disease, [1] liver cancer, [2] and pancreatic cancer. [3]